1. Introduction {#sec1}
===============

During the past few decades, scholars have extended significant effort to develop minimally invasive injectable remedies, using catheters or syringes, for targeted cell therapy and drug delivery \[[@bib1]\]. At the same time, hydrogels have gained importance as suitable scaffolding biomaterials for cell/drug delivery and regeneration of damaged tissues or organs \[[@bib2]\]. Hydrogels are two-component semi-solid system, composed of polymer and water, where the polymer forms an extensive network and water is trapped in it. Based on their rheological properties, hydrogels are viscoelastic in nature. Injectable hydrogels belong to a class of biomaterial that are frequently injected in liquid state, and then form a solid gel *in situ.* These types of hydrogels can be categorized based on their chemical or physical crosslinking property. The polymer networks can be formed either by the physical interactions between the polymer molecules or by forming a covalent chemical bond between one or more polymers or by a combination of these modes \[[@bib3], [@bib4], [@bib5]\] Structural, mechanical, and biological properties of injectable hydrogels are strongly influenced by the material cross-linking (type and concentration of physical or covalent bonding) properties. Injectable hydrogels should be porous, nontoxic, biocompatible (not harmful to living tissue), and have proper mechanical stability and biodegradability. Injectable hydrogels with higher mechanical stability exhibit improved cell-based tissue regeneration \[[@bib6]\] and serve as better delivery platforms due to their ability to control the diffusion of entrapped growth factors, nutrients or metabolites \[[@bib7]\]. The gelation kinetics of injectable hydrogels also plays an important role in its efficiency as a delivery scaffold. If the gel forms too fast, then it is difficult to inject and if it forms too slowly, then the network formation, adaption, and recovery may be too slow for effective 3D cell encapsulation as the solution can flow away from the injected site \[[@bib8]\]. Moderate to rapid rates of gel formation is desirable for most tissue engineering or drug/cell delivery applications as it facilitates a homogeneous cell distribution during encapsulation by preventing cell sedimentation or aggregation \[[@bib8]\]. Additionally, it prevents undesirable diffusion of the polymers away from the injection site before the gel formation \[[@bib9]\].

A newer approach of regenerative tissue engineering, involving injectable hydrogels, is based on shape memory polymers \[[@bib10], [@bib11], [@bib12], [@bib13], [@bib14]\]. Shape memory polymers are able to recover their original shapes after large deformation when subjected to external stimuli such as temperature, magnetism, moisture, or light \[[@bib10]\]. Previous reports have demonstrated that shape memory polymers can be promisingly used as injectable scaffolds in cell therapy \[[@bib12]\], cardiac tissue engineering \[[@bib13]\], bone tissue engineering \[[@bib14]\] etc. Another alternate strategy to enhance the therapeutic efficacy of injectable hydrogels is based on the use of shear thinning materials \[[@bib15],[@bib16]\]. In a shear thinning hydrogel, the gel has lower viscosity and flows under shear of injection. Once the shear stress is removed, gel restores its rigidity and remains localized at the point of injection \[[@bib15],[@bib16]\]. Colloid gels, derived from colloid particles, also displays shear thinning behavior \[[@bib17], [@bib18], [@bib19]\].

In the past few years, injectable hydrogels have gained notable attention for a wide range of clinical therapeutic applications, among them cardiovascular, endovascular, orthopedic, and dental \[[@bib20]\]. In this regard, one of the significantly important applications of injectable hydrogels is in neovascularization of ischemic tissues/organs such as ischemic heart, musculoskeletal, etc. \[[@bib21],[@bib22]\]. This specific application of injectable hydrogels is critically important, as vascularization remains to be one of the major bottlenecks in regenerative medicine. Neovascularization can take place by three processes: angiogenesis, vasculogenesis and arteriogenesis \[[@bib23]\]. Angiogenesis is the formation of new blood vessels from the existing blood vessels via migration, growth, and differentiation of endothelial cells (ECs) inside wall of blood vessels, whereas vasculogenesis is the formation blood vessel via *de novo* assembly of ECs \[[@bib23]\]. On the other hand, arteriogenesis is the increase in the diameter of existing arterial vessels. Injectable hydrogels derived from natural polymers such as fibrin and gelatin can promote neovascularization without incorporation of angiogenic factors or stem cells, due to their natural binding sites for solubilized growth factors and cellular integrin receptors \[[@bib21]\]. Neovascularization can be also triggered by incorporation of growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), angiopoitin-1 \[[@bib23]\], as well as VEGF mimetic synthetic peptides. Therapeutic neovascularization is expected to take place for several weeks or months with persistent stimulation of growth factors \[[@bib24]\]. However, the delivery of angiogenic growth factors alone based on a bolus injection results in a burst and short period of biological activity within the injured zone \[[@bib21]\]. With respect to cell-based therapies, in the majority of clinical trials, stem cells are injected directly in the ischemic area, which result in around 90% cell loss during injection \[[@bib22]\], and poor viability. Therefore, to prohibit cell loss and achieve prolonged and sustained release of angiogenic factors, injectable hydrogels have been at the center of attention for efficient delivery of growth factors or cells. In this review article, we report recent advancements in the development of injectable hydrogels, derived from natural and synthetic biomaterials, with an emphasis on their application in neovascularization via controlled delivery of angiogenic factors or cells (see [Table 1](#tbl1){ref-type="table"}).Table 1Brief summary of the injectable hydrogels and their effects during assay.Table 1HydrogelsAssayFactorsEffectChitosanIn vivoFGF-2Neovascularization by controlled growth factor release \[[@bib35]\].In vitro &AcellularBetter spreading and assembly of cultured HUVECs in the *in vitro* study \[[@bib36]\] and branching of capillary networks in the subcutaneous area \[[@bib36]\].In vivoIn vivoAcellularIncrease of M2 macrophage response and neovascularization \[[@bib34]\].In vitro &AcellularIncreased vasculogenesis in the *in vitro* study \[[@bib37]\] confirmed by significant angiogenesis and better blood circulation in the *in vivo* study \[[@bib37]\].In vivoIn vivoESC/bFGFImprovement of myocardial ischemia (MI) \[[@bib38], [@bib39], [@bib40]\].In vivoAcellularBetter angiogenic activity in peptide modified gel \[[@bib41]\].HAIn vivoEPCSignificant increase of vascularization leading to improvements in myocardial remodeling \[[@bib45]\]In vivoESARetention of the infarcted tissue by vasculogenesis \[[@bib46]\].In vivoAcellular & ADSCSignificant healing of the damaged skin by rapid cell proliferation and angiogenesis \[[@bib47],[@bib48]\].In vivoHADSCWound healing in the ischemic heart due to angiogenesis \[[@bib49]\].In vivoAcellularFunctional recovery of infarcted heart due to the increased number of arterioles and capillaries \[[@bib50]\]In vivobFGFConsiderable increase of neovascularization \[[@bib51]\].CollagenIn vivoAcellularAngiogenesis in the infarcted region of myocardium \[[@bib53]\].In vivoCACIncreased mechanical stability as well as expression level of proangiogenic cytokine \[[@bib54]\].In vivoPCHigher arteriole and capillary density in the hindlimb muscle \[[@bib55]\].Gelatin\
GHPA\
GelMAIn vivobFGFSignificant prolonged and transient neovascularization from bFGF loaded acidic and basic gelatin hydrogel respectively \[[@bib66]\].In vivobFGFSignificant increase of the collateral vessel formation with bFGF loaded AGHMs in the ischemic hindlimb \[[@bib67]\].In vitro &VEGFSustained release of VEGF from the gel with high bioactivity \[[@bib68]\]In vivoSignificant angiogenesis by the increase of blood vessel density \[[@bib68]\].In vivobFGF and BDNFHigher vessel density and LVEF in the ischemic myocardium \[[@bib69]\].In vivobFGF and hCDCNeoangiogenesis and significant retention of transplanted hCDCs in the ischemic area leading to improved cardiac function \[[@bib70]\].In vivoCMEfficient engraftment of CMs with the host and significant increase of angiogenic cytokines \[[@bib71]\].In vivoMSCExtensive neovascularization \[[@bib72]\].In vivoVEGFAngiogenesis in VEGF loaded GelMA hydrogel \[[@bib73]\].In vivoVEGFVascularization by significant increase of capillary and arteriole density in the infarct region, resulting in improved cardiac function \[[@bib75]\].FibrinIn vivoWith and without SMNeovascularization causing the reduction of infarcted myocardium both with or without SM \[[@bib78]\] as well as significant increase of cell survival \[[@bib79]\].In vivoAcellularNeovascularization resulting improvements in cardiac function by reducing infarct scar percentage \[[@bib80]\]. Significant increase of neovascularization of the bone-defect area \[[@bib72],[@bib83]\].In vitro &bFGFDecreased bFGF release rate in the *in vitro s*tudy was confirmed by increased neovascularization in the ischemic sites \[[@bib84]\].In vivoIn vitroVEGFIncreased growth of cells in the presence of VEGF modified fibrin gel \[[@bib85]\].In vivoVEGFAngiogenesis in the muscle indicated by significant increase in the vessel length density due to the controlled release of VEGF \[[@bib86]\].PNIPAAmIn vivobFGFIncreased angiogenesis resulting in a 2-fold improvement in relative blood flow to the infarcted myocardium \[[@bib89]\].Considerable recovery of cardiac function in the chronic infarcted myocardium due to increased angiogenesis \[[@bib90]\].PEGIn vivoVEGFSignificant neovascularization due to the sustained release of VEGF \[[@bib91]\].In vivoC16 and Ac-SDKPPromotion of angiogenesis, muscle regeneration and minimized detrimental inflammation in the peripheral artery disease \[[@bib92]\]In vivoVEGFNeovascularization by the sustained release of VEGF in the infract region \[[@bib93]\].In vivoVEGFEnhanced angiogenesis and space filling of the cornea micropocket \[[@bib94]\].In vivoHGF and VEGFSignificant increase in angiogenesis, stem cell recruitment, and decrease in fibrosis was observed in the dual growth factor delivery group \[[@bib95]\].In vivoCPCNon-adhesive RDG gels codelivered with CPCs showed improved cardiac function whereas ECM-derived adhesive peptide-presenting gels failed to show the recovery of cardiac function \[[@bib96]\].In vivoVEGFLowest degradation time for *in situ* polymerized hydrogel and highest vascularization from the injectable microbeads due to the VEGF release \[[@bib97]\].PLGASignificant enhancement of angiogenic activity due to the controlled release of bFGF in the ischemic tissue \[[@bib99]\].Synthetic peptideIn vitro &IGF-1CIncreased stem cell viability in presence of IGF-1C hydrogel in the *in vitro* and *in vivo* study resulting in the increase of *in vivo* angiogenesis \[[@bib100]\].In vivoADSCIn vivoAcellularIncreased blood vessel formation in the VEGF memetic peptide than non angiogenic peptide \[[@bib101]\]. Formation of mature blood vessels and preservation of ischemic tissue structure and function \[[@bib102]\].

2. The classes of injectable hydrogels {#sec2}
======================================

Injectable hydrogels are derived from biomaterials, that can be natural or synthetic or a combination of these referred to as hybrid. Chemical structures of a few of these natural and synthetic polymers have been presented in [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}. These biomaterials are used alone or in mixtures, can give rise to the formation of polymers with various properties \[[@bib25]\]. The choice of biomaterial for the injectable hydrogel is a critical aspect for a specific target application. The biomaterial should be non-toxic, biodegradable and able to integrate with the host tissue. Natural polymers such as chitosan, gelatin, fibrinogen, hyaluronic acid and collagen have advantages over synthetic polymer as they promote cellular adhesion and infiltration due to the presence of cell adhesion moieties. Natural polymers also contain specific bioactive molecular domains that can enhance biological interactions between the material and the host \[[@bib26], [@bib27], [@bib28]\]. These polymers, including injectable hydrogels, have already been used in clinical applications \[[@bib27],[@bib28]\].Fig. 1(i-iv) Chemical structure of natural polymers being used as injectable hydrogel scaffold. (v) Representative H&E stained histological images of the vascularization for the different groups of injected chitosan hydrogel using rat model on day 4, 8, and 14 post-injection. (vi) Quantification of capillary number for different injection groups on Day 4, 8 and 14. (Adapted with permission from Elsevier \[Biomaterials\] copyright (2004)\[35\]. (vii) Representative H&E stained histological images of skin and subcutaneous tissue after 14 days of surgery with different groups of implantation. (vii) Neovascularization index after day 14 of the surgery. (Adapted with permission from Elsevier \[Biomaterials\] copyright (2005) \[[@bib51]\].Fig. 1Fig. 2(i-ii) Chemical structures of synthetic polymers being used as injectable hydrogel scaffold. (iv) Angiogenic effects due to the release of bFGF from pH-responsive p (NIPAAm-co-PAA-co-BA) hydrogel. Representative images of the histological sections of the tissues with rat endothelial cell antigen-1 (RECA-1) staining (a-d) and smooth muscle α-actin (α-SMA) staining (f-i). Quantification of capillary density by RECA-1 (v) and arteriolar density by α-SMA (vi) staining. (Adapted with permission from Elsevier \[Biomaterials\] copyright (2011)\[89\]. (vii) Schematic representation of proposed mechanism of wound healing using nanofibrous SLanc hydrogels (A-D). (Adapted with permission from ACS Publications \[ACS Nano\] copyright (2015) \[[@bib101]\].Fig. 2

On the other hand, synthetic hydrogels have several advantages over natural hydrogels. Synthetic hydrogels readily allow precise control over critical material properties including polymerization, degradation and mechanical stiffness. Synthetic polymers have been hybridized with natural biopolymers to engineer native like extracellular matrix (ECM) with controlled biophysical and biochemical properties. In the following sections we will cover different types of natural and synthetic injectable hydrogels, which have been used for neovascularization application \[[@bib28]\].

2.1. Natural injectable hydrogels for neovascularization {#sec2.1}
--------------------------------------------------------

### 2.1.1. Chitosan {#sec2.1.1}

Chitosan (CS) is a linear polysaccharide composed of [d]{.smallcaps}-glucosamine and *N*-acetyl-[d]{.smallcaps}-glucosamine. It is prepared by deacetylation of chitin from crustacean shells \[[@bib29]\] with an alkaline substance like sodium hydroxide. CS has been widely used in several biomedical applications \[[@bib30], [@bib31], [@bib32], [@bib33]\] because of its biocompatibility, biodegradability, antimicrobial property, nontoxicity, and proper cell binding capability. However, the poor solubility of chitosan in physiological solvents, such as phosphate buffer saline (PBS) makes it challenging for the use in the form of an injectable hydrogel scaffold \[[@bib34]\]. To address this problem, investigators have produced hydrogels by mixing chitosan with other natural polymers \[[@bib28]\] for the formation of bio-hybrid injectable scaffolds. Apart from poor solubility, fast biodegradation *in situ* and possible allergic reactions of the residual proteins during chitosan preparation are some of the other major disadvantages of chitosan-based biomaterials \[[@bib29]\].

To date, several chitosan-based hydrogels have been developed for delivery of growth factors and stem cells for neovascularization. For example, an injectable chitosan/heparinoid hydrogel was used by Fujita et al. for entrapment and sustained release of FGF-2 for neovascularization in a mouse model \[[@bib35]\]. Significant increase in the formation of capillary networks after the injection of FGF-2 loaded hydrogel as compared to the injection of FGF-2 alone confirmed that the promotion of neovascularization was due to controlled growth factor release ([Fig. 1](#fig1){ref-type="fig"}v and vi).

Several acellular neovascularization approaches have also explored the use of chitosan based hydrogels. For instance, Deng et al. studied vasculogenesis *in vitro* by human umbilical vein endothelial cells (HUVECs) using collagen-chitosan injectable hydrogel \[[@bib36]\]. In this study, chitosan was added in different ratio to a collagen matrix via 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC-NHS) chemistry. Several studies on the physical properties including injectability, denaturation temperature, and the mechanical strength measurements indicated that the gel strength enhanced with the increased ratio of chitosan, leading to better spreading and assembly of HUVECs. Specifically, the authors suggested that a higher ratio of chitosan in the gel enhanced the tubular network formation by HUVECs by increasing 'total capillary tube length' and 'total area covered'. The result of the *in vitro* study was supported by *in vivo* study, performed by acellular implantation of the hydrogel scaffold via subcutaneous injection, where branching of capillary networks was observed only in collagen:chitosan with 1:1 ratio. In another study, Deng et al. used an injectable chitosan-based hydrogel to study the tissue regeneration in the defected abdominal wall of a rat model \[[@bib34]\]. The gel was formed via Schiff base reaction of N,O-carboxymethyl chitosan (NOCC) and aldehyde hyaluronic acid (A-HA). The gelation time of this hydrogel was tunable by altering the ratio of NOCC and A-HA and hence it could be optimized for injection in the affected tissue zone. Considerable increase of M2 macrophage response and neovascularization in the defected wall was observed causing anti-inflammation, tissue repair and remodeling of the affected area in response to the injected hydrogel. The authors suggested that vascularization was promoted due to the sufficient supply of nutrients and oxygen to the cells because of the enhanced porosity of the three-dimensional (3D) structure of the hydrogel matrix. Recently, a novel chitosan-fibrin-based self-healing hydrogel was developed by Hsieh et al. \[[@bib37]\]. In this study, a chitosan-based interpenetrating polymer network (IPN) hydrogel (composition: 1.5% glycol chitosan, 1% difunctional poly (ethylene glycol) (PEG), 0.005% fibrinogen and 0.002% thrombin) was used to study *in vitro* vasculogenesis using ECs. Polymerase chain reaction (PCR) data indicated an increased level of 'vasculogenesis marker gene expression' leading to significantly increased branch length and branch point density of the endothelial network within the IPN gel compared to control gel (fibrin hydrogel consisting 0.5% fibrinogen and 0.2% thrombin). Also, in an *in vivo* study, injection of this chitosan-fibrin hydrogel in zebrafish and mice models demonstrated significant angiogenesis in the perivitelline space of zebrafish and enhanced blood circulation in the ischemic hindlimbs of mice.

Chitosan-based injectable hydrogels have also been widely used in cardiac tissue engineering to promote vasculogenesis/angiogenesis. Wang et al. studied the improvement of myocardial ischemia (MI) healing by co-injection of chitosan hydrogel with embryonic stem cell (ESC) or bFGF \[[@bib38], [@bib39], [@bib40]\]. After MI, the infarcted myocardium undergoes hypoxia due to lack of functional vasculogenesis limiting the supply of oxygen to the injured tissue. A synthetic peptide (RoY) modified chitosan-based injectable hydrogel was prepared by the same group to address this problem \[[@bib41]\]. For preparing this hydrogel, chitosan chloride was reacted to the RoY synthetic peptide forming a chitosan-peptide (CS-RoY) conjugate via an amide linkage. Vascularization was studied *in vitro* with HUVECs under hypoxia as well as in an *in vivo* rat model. The results showed better angiogenic activity in CS-RoY gel compared to chitosan gel. The authors explained this phenomenon as the activation of Akt and ERK1/2 signaling pathways by the expression of GRP78 receptors of HUVECs, which is related to their survival and proliferation.

### 2.1.2. Hyaluronic acid {#sec2.1.2}

Hyaluronic acid (HA) or hyaluronan, is a unique anionic, nonsulfated glycosaminoglycan, biosynthesized at the plasma membrane which is distributed in connective, epithelial, and neural tissues \[[@bib42]\]. It is a linear polymer, comprising of repeated disaccharide unit of [d]{.smallcaps}-glucuronic acid and *N*-acetyl-[d]{.smallcaps}-glucosamine. HA is one of the chief components of the ECM, and plays a significant role in cell proliferation and differentiation \[[@bib43]\]. A number of approaches have been utilized chemical and physical crosslinking techniques to improve the mechanical properties, biodegradation, and biocompatibility of HA as an injectable hydrogel \[[@bib44]\] for cell-based therapies. For instance, in a recent study by Gaffey endothelial progenitor cells (EPC) were delivered into ischemic myocardium using a novel injectable shear thinning HA hydrogel \[[@bib45]\]. This hydrogel was assembled by host-guest interaction of both adamantine and β-cyclodextrin modified HA. A significant increase of vascularization was found in EPC embedded gel constructs, leading to improved ventricular function and myocardial remodeling, compared to blank gel or bolus injection of EPCs. MacArthur et al. developed a HA-based injectable hydrogel for sustained release of engineered stromal cell-derived factor (ESA) (4 weeks) to preserve ventricular function after MI in a rat model \[[@bib46]\]. The gel was a hydroxyethylmethacrylate modified HA with terminal double bonds which underwent free radical initiated crosslinking. ESA is an EPC chemokine, which induced EPC to retain in the infarcted tissue of rat in an *in vivo* study and subsequently promoted vasculogenesis. In another study, an HA-chitosan injectable hydrogel was developed by Jiang et al. for promoting skin regeneration in a mouse skin defect model \[[@bib47]\]. The aldehyde group modified HA was reacted with chitosan to form the gel network via Schiff base linkage between aldehyde and amine groups of chitosan. The authors observed significant wound healing upon injection of this hydrogel in damaged skin attributed to rapid cell proliferation and angiogenesis. Later, the same group performed a cell therapy study with the same HA-chitosan hydrogel \[[@bib48]\]. The synthesized hydrogel was used as a carrier for injection of adipose derived stem cells (ADSC) into a skin defect mouse model. The author claimed that this cell-laden hydrogel accelerated wound closure by enhancing the cell proliferation and angiogenesis. Park et al. also used a HA-based injectable hydrogel as a carrier of human adipose derived stem cell (HADSC) for tissue regeneration in healing of tissue defects \[[@bib49]\]. In this study, a catechol functionalized HA-based hydrogel was synthesized by reaction between HA and dopamine hydrochloride via EDC-NHS chemistry and the gel was used to test its efficacy in a tissue defect model. The cell-laden hydrogel was injected in ischemic hind limb of mouse as well as in a critical size bone-defect model. High cellular viability, up to day 7, indicated the biocompatibility of the hydrogel, while the ELISA data confirmed high levels of VEGF secretion from the cell-laden hydrogel. The authors suggested that wound healing within the ischemic area was promoted by angiogenesis, triggered by survival and migration of the ECs. In another study, Yoon et al. developed a HA-based hydrogel that was able to restore the functionalities of infarcted rat heart upon injection without presence of any stem cell or growth factor \[[@bib50]\]. The hydrogel was formed using Michael-type addition reaction between acrylated HA and thiolated PEG. From the histological studies, the authors observed that the numbers of arterioles and capillaries were increased by 152% and 148% in the infarcted region upon injection of the HA hydrogel. In another study, Cai et al. developed a thiol modified HA-heparin conjugate along with a thiol modified chondroitin sulfate-heparin hydrogel for tissue vascularization \[[@bib51]\]. The role of thiolated heparin was to provide a cross-linkable analog with the thiolated HA or chondroitin sulfate. They incorporated basic fibroblast growth factor (bFGF) within the hydrogel and assessed the efficacy of vascularization *in vivo*. The synthesized biomaterial was biodegradable, injectable and capable of controlled release of bFGF. Upon injection of the hydrogel into subcutaneous pockets in Balb/c mice, considerable increase of neovascularization was observed with HA and chondroitin sulfate hydrogels containing both bFGF and cross-linked heparin ([Fig. 1](#fig1){ref-type="fig"} vii and viii). In contrast, hydrogels without bFGF and/or cross-linked heparin showed minimal increase in neovascularization.

### 2.1.3. Collagen {#sec2.1.3}

Collagen is the main structural protein of the ECM of skin, bone, tendons, ligaments, and cartilage of mammalian tissues \[[@bib28]\]. Collagen type I is the most copious in human body \[[@bib23]\]. Collagen is thermo-reversible, biocompatible and amenable to enzymatic (collagenase) degradation. However, high synthesis cost, low physical strength, poor mechanical stability are significant challenges associated with the use of collagen \[[@bib28]\]. Collagen has been engineered by chemical cross-linking with different substrates for improvement of its physical strength and cell adhesion capacity \[[@bib28]\]. Additionally, collagen has been successfully used as a natural hydrogel for repair of MI *in vivo*. However, vascular formation is strongly dependent on the concentration of collagen. For example, Dai et al. injected 100 μL of 65 mg/mL collagen hydrogel \[[@bib52]\] and Huang et al. injected 50 μL of 1 mg/mL collagen hydrogel \[[@bib53]\] in a rat MI model. The first group found no angiogenesis in the infarcted region although the wall thickness increased six-week post injection. On the other hand, the second group found considerable amount of angiogenesis after 5 weeks of injection. Therefore, based on these studies, proper optimizations of the concentration of collagen in the hydrogels could impact the efficiency of vascularization and myocardial repair.

MaBane et al. developed a collagen:chitosan (10:1) injectable hydrogel with and without circulating angiogenic cells (CACs) to generate a pro-angiogenic environment in a type 1 diabetic (T1D) mouse model \[[@bib54]\]. The mechanical stability of collagen-chitosan gel was found to be higher than pure collagen gel, with enhanced CACs cellular viability. Within the *in vivo* experiments, collagen-chitosan gel was implanted subcutaneously in a T1D mouse model. Although the authors observed increased expression of proangiogenic cytokines in collagen-chitosan implants, they did not observe significant neovascularization.

Collagen-derived injectable hydrogels have also been used for cell-based therapies. Suuronen et al. demonstrated a novel technique for expansion and delivery of CD133^+^ progenitor cells with improved capacity of vascularization \[[@bib55]\]. Adult human CD133^+^ progenitor cells (PC) were loaded in an injectable collagen-based matrix and delivered into the ischemic hindlimb of athymic rats to study vascularization. Immunohistochemistry of hindlimb muscle after 2 weeks of treatment indicated higher density of arterioles and capillaries as compared to other treatment groups receiving injections of phosphate-buffered saline, matrix, or only CD133^+^ cells.

### 2.1.4. Gelatin {#sec2.1.4}

Gelatin is essentially a denatured collagen, synthesized by acid or alkaline hydrolysis of collagen \[[@bib23]\]. Gelatin forms a thermo-reversible, transparent gel below the sol-gel transition temperature (∼40 °C) via physical interactions between collagen molecules \[[@bib23]\]. Gelatin-based hydrogels do not enhance thrombogenicity and have pro-angiogenic properties \[[@bib56]\]. Therefore they have been used as a scaffolding biomaterial for tissue engineering of 'highly' vascularized organs \[[@bib57]\] and also in the cell-based therapies after heart failure. Additionally, derivatives of gelatin has shown promising applications for tissue regeneration \[[@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64]\], cancer studies \[[@bib60]\] as well as for angiogenic growth factor delivery and vascularization \[[@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib74], [@bib75]\] due to the presence of bioactive sequences \[[@bib23]\]. Tabata et al. studied the release of bFGF incorporated in both acid and basic gelatin-based hydrogels to promote neovascularization induced by the biodegradation of the hydrogels \[[@bib66]\]. For preparing the hydrogel, aqueous solution of bFGF was primarily absorbed in gelatin. bFGF, being positively charged, complexes with acidic gelatin, but not in basic gelatin. Therefore, the release of bFGF from acidic gelatin was better sustained (only 30% in 1 day in PBS at 37 °C) compared to basic gelatin (100% in the same time frame). Significant prolonged neovascularization was observed when bFGF loaded acidic gelatin was injected into ischemic mouse model. The period of neovascularization could be altered by changing the water content in the gelatin hydrogel. On the other hand, only transient neovascularization was observed with the basic gelatin hydrogel. The authors suggested that prolonged vascularization was due to sustained release of bFGF from acidic gelatin hydrogel and transient vascularization was due to the initial burst release of bFGF from basic gelatin hydrogel. This observation was later confirmed in another study by Hosaka et al. \[[@bib67]\]. They developed functional collateral vessels by injection of bFGF-loaded acidic gelatin hydrogel microspheres (AGHMs) in a hindlimb ischemia model of rabbit. Percentage of delivered bFGF was dependent on the diameter of the microspheres. Twenty eight days post-injection, a significant increase of collateral vessel formation was observed in bFGF loaded AGHMs as compared to PBS (i.e. control) treated AGHMs. In another study, Li et al. developed a modified gelatin-based hydrogel to study angiogenesis by the release of VEGF in a mouse model \[[@bib68]\]. For the hydrogel (G:gelatin/T:tyramine/H:heprin) preparation, gelatin (G) was reacted first with tyramine (T) to provide enzymatic crosslinking points and then with heparin (H) to provide the binding domains to VEGF. In the *in vitro* studies, the authors observed sustained release of VEGF from the G/T/H gel with high bioactivity for 3 weeks. In the *in vivo* studies, significant increase of blood vessel density in 2 weeks post-injection of VEGF loaded G/T/H gel at the wound area indicated enhanced angiogenesis by the release of VEGF compared to the controls.

Gelatin hydrogel has been also used to study the synergistic effect of multiple growth factor delivery on angiogenesis. For instance, Liu et al. incorporated bFGF and brain-derived neurotrophic factor (BDNF) in a gelatin-based hydrogel to study the simultaneous effect of both factors on angiogenesis in an ischemic myocardium \[[@bib69]\]. Upon formation of higher vessel density and higher left ventricular ejection fraction (LVEF) in the hydrogel embedded with bFGF + BDNF as compared to only bFGF, the authors claimed that the former system might become a promising therapeutic strategy for the treatment of ischemic myocardium.

In other studies, gelatin hydrogel has been used as a carrier for cell therapy, along with controlling the delivery of growth factor. For instance, Takehara et al. studied whether the release of bFGF from a gelatin hydrogel could improve human cardiosphere-derived cell (hCDC) therapy in a chronic MI pig model \[[@bib70]\]. In one their experimental setting, the authors injected gelatin hydrogel incorporated with or without bFGF. In other experiments, bFGF- gelatin hydrogel with or without hCDC was injected. Neoangiogenesis by increasing arteriolar density was observed in the ischemic myocardium resulting in improved cardiac function. Their findings also revealed significant retention of transplanted hCDCs in the ischemic area, improving the infarct size, when combined with bFGF-loaded hydrogel as compared to hCDC injection alone. In another study by Nakajima et al., gelatin hydrogel was used for transplanting cardiomyocytes (CM) in an infarcted rat myocardium to assess improvement in cardiac function \[[@bib71]\]. In this study, rat CM were transplanted with gelatin hydrogel to infarcted hearts and compared with sham operated rats, CM in PBS, only PBS, and only hydrogel transplanted groups. After three weeks of transplantation, pathological analysis showed that in the CM loaded hydrogel group, the cells were efficiently engrafted with the host and angiogenesis was significantly increased in the infarcted area. Also, according to quantitative RT-PCR analysis, significant increase of angiogenic cytokines, such as bFGF, VEGF, and hepatocyte growth factor (HGF), were observed in CM loaded hydrogel group compared to the other experimental groups.

To increase its cross-linking sites, make it more stable at the body temperature and reduce its degradation rate, gelatin has been chemically functionalized with several cross-linkable substrates like hydroxyphenyl propionic acid to produce Gelatin-Hydroxyphenyl Propionic Acid (GHPA) \[[@bib72]\] or with unsaturated methacrylate groups to produce gelatin methacrylate (GelMA) \[[@bib73]\]. GHPA undergoes in-situ oxidative crosslinking while GelMA undergoes photo-initiated polymerization forming a suitable injectable hydrogel for growth factor or gene delivery as well as cell-based therapy. Lee et al. used mesenchymal stem cell (MSC) loaded GHPA for endothelial differentiation of MSCs and tubule formation *in vivo* \[[@bib72]\]. Extensive neovascularization was observed in two weeks post-injection. In another study, Lai et al. modified a GelMA hydrogel with carboxybetaine methacrylate (CBMA) (i.e. GelMA/CBMA hydrogel) with better mechanical properties, lower degradation rate, and controlled drug release rate in comparison to only GelMA group to promote vascular formation \[[@bib74]\]. These properties of GelMA/CBMA hydrogels were tunable by varying the ratio of CBMA. In an *in vivo* mice model, angiogenesis was observed in VEGF loaded GelMA/CBMA hydrogel. The authors claimed that these properties make the GelMA/CBMA hydrogel a promising material for drug delivery, vascularization and tissue regeneration. In a recent study, Paul et al. used GelMA-graphene oxide hydrogel for angiogenic gene delivery and to promote vasculogenesis and cardiac repair \[[@bib75]\]. Graphene oxide and VEGF loaded GelMA hydrogel were injected in a rat MI model. Significant increase in capillary density confirmed vasculogenesis in the infarct region, resulting in improved cardiac function.

### 2.1.5. Fibrin {#sec2.1.5}

Fibrin is a water-soluble fibrous glycoprotein present as a major component in blood clots. Clinical-grade fibrin is obtained by processing blood plasma. Fibrin gel is known to have angiogenic effect, due to its molecular properties \[[@bib76]\]. Therefore it has been used as a biodegradable, injectable scaffold for promoting angiogenesis/vasculogenesis in tissue engineering \[[@bib77]\].

Christman performed the pioneer work on the use of fibrin gel for cardiac regeneration \[[@bib78],[@bib79]\]. In an early study, they restored cardiac function in an ischemic rat myocardium by injecting "fibrin glue" with or without skeletal myoblast (SM) \[[@bib78]\]. The "fibrin glue" is a fibrin hydrogel which is the mixture of two components, (1) concentrated fibrinogen and aprotinin and (2) thrombin and CaCl~2~. The authors proposed that a reduction of infarcted myocardium could be induced by neovascularization following injection of fibrin glue, both with or without SM. Later, they studied the survival of SM in the fibrin glue *in vitro* as well as using an ischemic rat myocardium model *in vivo* \[[@bib79]\]. Cell survival was determined by measuring infracted area, covered by cells. Five weeks after injection, SM loaded fibrin glue was found to cover the infracted area to a significantly higher extent than the control groups including BSA and myoblast loaded BSA. The authors suggested that the increase of cell survival in fibrin glue was due to its function as a temporary extracellular matrix for the transplanted cells. Because of the greater biocompatibility, fibrin glue also induced neovascularization in the infarct region by significant increase of the arteriole density in comparison with the control groups. A comparative study on the therapeutic effects of acellular fibrin and alginate gels was also performed in a rodent model of chronic ischemic cardiomyopathy by Yu et al. \[[@bib80]\]. The authors observed improvements in cardiac function by reducing infarct scar percentage and neovascularization with injection of both fibrin and alginate gel compared to the injection of PBS, claiming these gels as potentially effective injectable biopolymers for myocardial repair.

Numerous attempts have been also undertaken for healing irregular bone defects using fibrin-based gels. However, in most cases complete regeneration has not possible due to a lack of vascularization \[[@bib81]\]. As fibrin gel is known to have angiogenic property, large quantities of fibrin are required for the use as a scaffolding biomaterial for bone healing, which is not cost effective. Recently, two research groups tried to overcome this problem by introducing fibrin nanoparticle in chitin-based injectable hydrogel \[[@bib82],[@bib83]\]. Fibrin nanoparticles were prepared using a modified water-in-oil emulsification-diffusion method in absence of any surfactants. Both group observed a significant increase in neovascularization of the bone-defect area in presence of fibrin nanoparticle containing hydrogel as compared to the control groups.

Fibrin gel has also been used to deliver growth factors for vascular formation or transplant cells in clinical applications. However, low binding affinity between fibrin and growth factors as well as fast degradation of the hydrogel often leads to rapid release of growth factors. In this regard, several attempts have been taken to address controlled delivery of growth factors from fibrin gel. For instance, Jeon et al. hypothesized that the rate of bFGF release from fibrin gels can be controlled with the use of heparin and varying concentrations of fibrinogen and thrombin \[[@bib84]\]. They observed that bFGF release rate decreased upon addition of heparin and with increased concentrations of both fibrinogen and thrombin. Significant increase of *in vitro* dermal fibroblast growth in culture containing bFGF-loaded media compared to normal media indicated the bioactivity of bFGF. Therapeutic capacity of the bFGF delivery system was studied by *in vivo* experiments, where bFGF-loaded fibrin gels were injected into mice ischemic limbs. Four weeks post injection, quantification of capillary density and capillary ratio per muscle fiber, in the ischemic sites, indicated enhanced neovascularization by the injection of bFGF-loaded fibrin gels as compared to the control receiving no treatment.

Zisch et al. introduced an injectable "fibrin glue" by creating mutant α~2~-PI~1-8~ --VEGF~121~ fusion protein (to control the release of VEGF) and incorporating it into fibrin hydrogel to promote its angiogenic activity \[[@bib85]\]. Effect of VEGF on EC growth was studied by seeding HUVECs on α~2~-PI~1-8~--VEGF~121~ modified fibrin hydrogel. Increased percent of cell-growth was observed up to day four of culture in the presence of VEGF modified fibrin gel as compared to control non-modified fibrin gel. The authors claimed that the incorporation of increasing amounts of α~2~-PI~1-8~--VEGF~121~ in fibrin hydrogel resulted in dose-dependent enhancement of EC growth that could be applied into an ischemic region to provide angiogenic activity. A few years later, in a similar work, Sacchi et al. developed a less degradable modified fibrin hydrogel to control the dose of VEGF, that is delivered to the tissue, for inducing stable and functional angiogenesis \[[@bib86]\]. For controlling the release of VEGF from the hydrogel, murine VEGF~164~ was fused with α~2~-plasmin inhibitor (α~2~-PI~1--8~) to form α~2~-PI~1--8~-VEGF~164~ and then crosslinked with fibrin. In addition, Aprotinin-α~2~-PI~1--8~ was synthesized and incorporated in the gel to control the degradation rate. Intramuscular injection of the hydrogel (combination of Fibrin- α~2~-PI~1--8~- VEGF~164~ and Aprotinin-α~2~-PI~1--8~) in a mice model provided stable and functional angiogenesis for four weeks, as indicated by significant increase in the vessel length density due to the controlled release of VEGF.

2.2. Synthetic injectable hydrogels for neovascularization {#sec2.2}
----------------------------------------------------------

### 2.2.1. *N*-isopropylacrylamide copolymer {#sec2.2.1}

*N*-isopropylacrylamide copolymer (PNIPAAm)-based hydrogels are injectable at room temperature but they solidify in the body due to the increase in the temperature. These gels can efficiently be designed for cellular delivery and promoting cell attachment, spreading and within the target tissue \[[@bib87]\]. However, non-resorbability of NIPAAm copolymer limits its application in short term/transient applications due to potential chronic inflammatory response in the body. To address this problem, several groups have made NIPAAm copolymers biodegradable by incorporating biodegradable groups in the polymer \[[@bib88]\].

Garbern et al. developed a pH- and temperature-responsive NIPAAm-based hydrogel with a synthetic random copolymer of poly (*N*-isopropylacrylamide-co-propyl acrylic acid-co-butyl acrylate) (p \[NIPAAm-co-PAA-co-BA\]), for therapeutic angiogenesis \[[@bib89]\]. The developed P(NIPAAm-co-PAA-co-BA) formed gel at pH 6.8 at 37 °C while remained as a solution at pH 7.4 at the same temperature. When the copolymer solution was injected with bFGF in the rat ischemic myocardium, it formed gel in the acidic environment of the ischemic area. Polymer plus bFGF treatment led to 30--40% increase of capillary densities resulting in a 2-fold improvement in relative blood flow toward the infarct region, compared to saline plus bFGF or polymer-only controls in a twenty eight days post injection period ([Fig. 2](#fig2){ref-type="fig"} iv, v and vi). The authors suggested that the improvement of angiogenesis was due to the sustained, local delivery of bFGF. In another study, Fujimoto et al. synthesized a thermo-responsive and biodegradable NIPAAm copolymer hydrogel for repair and healing of chronic infarcted myocardium in a rat model \[[@bib90]\]. NIPAAm was modified with poly (trimethylene carbonate) (PTMC) to lower the hydrolysis rate of the injected hydrogel *in vivo*. Upon eight weeks of injection, considerable recovery of cardiac function took place following enhanced angiogenesis as compared to the control saline injection.

### 2.2.2. PEG {#sec2.2.2}

PEG is a widely used synthetic biomaterial in biomedicine due to its extremely low cytotoxicity and immunogenicity \[[@bib23]\]. PEG-based hydrogels are formed by covalent crosslinking between its chains and provide several advantages for regenerating various types of tissues such as bone and blood vessels \[[@bib16]\]. Although PEG-based gels are widely used in engineering of patches or tissue constructs, a few research groups have developed injectable PEG based hydrogel for therapeutic angiogenesis. Phelps et al. engineered PEG-based synthetic hydrogel containing protease-degradable sites, cell-adhesion motifs (RGD: arginine-glycine-aspartic acid), and VEGF growth factor for neovascularization \[[@bib91]\]. In a mouse model of hind-limb ischemia, significant increase of vessel density was observed at 4 weeks of hydrogel injection as compared to the injection of only VEGF due to the sustained cell-demanded release of VEGF. The lower degradation rate of the hydrogel led to slow release of VEGF, as VEGF release took place during the degradation of the hydrogel. Zachman et al. developed a PEG-based injectable hydrogel that enabled controlled, dual delivery of proangiogenic C16 and anti-inflammatory Ac-SDKP peptides in the mouse model of peripheral artery disease (PAD) \[[@bib92]\]. The combined injection of C16 and Ac-SDKP peptides promoted angiogenesis, muscle regeneration and minimized detrimental inflammation by regulating TNF-α pathways separately from MMP-9 mediated pathways of angiogenesis. Rufaihah et al. took a different attempt to achieve controlled release of VEGF \[[@bib93]\]. They developed an injectable PEGylated fibrin hydrogel, which could store and sustain release of VEGF. The hydrogel was formed by covalent linkage between fibrinogen and PEG diacrylate. In an *in vivo* study, the hydrogels were injected in a MI model, where significant increase of arteriole density in infarct and peri-infarct regions indicated neovascularization, through sustained release of VEGF from the loaded fibrin gel. Leslie-Barbick et al. developed a PEG-based hydrogel, covalently linked with QK peptide, a VEGF memetic peptide, (Sequence: Ac-KLTWQELYQLKYKGI-amide) that is known to promote angiogenesis \[[@bib94]\]. In an *in vivo* study, the authors incorporated releasable VEGF alone and in combination with PEG-VEGF or PEG-QK hydrogel which were implanted into the mouse cornea micropocket. Fourteen days after implantation, PEG-QK hydrogel showed enhanced angiogenesis by increasing vessel density and branch points as well as space filling of the cornea micropocket. In another study, Salimath et al. developed a PEG-based hydrogel having protease-degradable crosslinker, which underwent collagenase degradation \[[@bib95]\]. In an *in vivo* study in a rat MI model, the hydrogel, incorporated with either hepatocyte growth factor (HGF) or VEGF or both, was delivered to the infarcted myocardium. Significant increase in angiogenesis, stem cell recruitment, and decrease in fibrosis were observed in the dual growth factor delivery group compared with single growth factor therapy. In a recent study by Bhutani et al., PEG-based hydrogel presenting ECM derived adhesion peptides (RGD and GFOGER -a collagen mimicking peptide) and control scrambled non-adhesive peptide (RDG) were prepared and their effects on behavior of cardiac progenitor cells (CPCs) *in vitro* as well as cardiac repair in rats undergoing ischemia reperfusion were monitored \[[@bib96]\]. GFOGER gels induce differentiation of CPCs toward CMs and lowered the levels of reparative secretive factors. In contrast to expectations, in the *in vivo* study, improved cardiac function was observed only with the non-adhesive RDG gels co-delivered with CPCs. However, ECM-derived adhesive peptide-presenting gels failed to show the recovery of cardiac function. Increased angiogenesis was observed for both RGD and RDG gels and less for GFOGER gel. Berdichevski et al. performed an interesting comparative *in vivo* study of biodegradation and angiogenic response with three types of VEGF bearing PEG-fibrinogen hydrogel configurations in a subcutaneous rat implantation model \[[@bib97]\]. The three types of implants were made of identical amounts of precursors namely, cylindrical plugs, injectable spherical microbeads and *in situ* polymerized injectable hydrogels. According to the MRI data, the degradation time of *in situ* polymerized hydrogel was lowest and cylindrical plug was highest. Significant increase of vascularization (16-fold more capillaries) was resulted by the *in vivo* VEGF release from the microbeads in comparison with controls. Based on these data, the authors claimed that implantation strategies could have significant effect on neovascularization triggered by localized growth factor delivery.

### 2.2.3. Poly(Latic-co-glycolic acid) {#sec2.2.3}

Poly (Latic-co-glycolic Acid) (PLGA) is a frequently used biodegradable synthetic polymers, utilized as a 3D scaffolding biomaterial, for tissue regeneration and repair. PLGA is a copolymer of two different monomers, glycolic acid and lactic acid. PLGA is one of the usual choices in the fabrication of several FDA approved biomedical devices, such as, grafts, sutures, implants, prosthetic devices, surgical sealant films, micro and nanoparticles. PLGA microspheres have been successfully used for gradual delivery of cells or drugs in experimental stroke models \[[@bib98]\]. Injectable PLGA nanospheres/microspheres have been developed for prolonged neovascularization in ischemic models. For instance, Jeona et al. aimed to achieve enhanced angiogenic activity by prolonged release of bFGF from an injectable fibrin gel using PLGA nanospheres. A novel heparin conjugated PLGA nanospheres (HCPNs) was fabricated by reacting aminated PLGA with heparin via EDC/NHS chemistry. bFGF was then entrapped in HCPNs and subsequently was suspended in the fibrin gel. The authors observed prolonged release of bFGF from HCPN loaded fibrin gel as compared to blank fibrin. Significant increase of capillary formation, in an ischemic mouse model, after 4 weeks of injection with HCPN loaded fibrin gel indicated enhanced angiogenic activity due to the controlled release of bFGF \[[@bib99]\].

### 2.2.4. Synthetic peptides {#sec2.2.4}

A number of growth factor mimetic peptides have also been developed for induction of angiogenesis through cellular signaling. For instance, VEGF mimetic peptides promote angiogenesis by prolonged stimuli presentation and residence time *in situ*. Previous works have focused on the development of injectable hydrogel by immobilizing these peptides via covalent bonding in the hydrogel scaffolds \[[@bib41],[@bib100]\]. Controlled release of peptide will take place during the degradation of the hydrogel. For instance, Feng et al. synthesized a chitosan-based hydrogel by immobilizing the C domain peptide of insulin-like growth factor-1 (IGF-1C) for a successful stem cell therapy in acute kidney injury (AKI) \[[@bib100]\]. *In vitro* studies indicated increased cell viability in chitosan-IGF-1C hydrogel compared to blank chitosan hydrogel. *In vivo* implantation of the chitosan--IGF-1C hydrogel and ADSCs in ischemic kidneys resulted in enhanced stem cell survival and angiogenesis. The authors claimed that IGF-1C immobilized chitosan hydrogel provides a promising therapeutic approach for AKI. In another study, Kumar et al. synthesized a VEGF memetic peptide \[SLanc: K-(SL)3 (RG) (SL)3-K-G-KLTWQE-LYQLKYKGI\] and a non-angiogenic mimic peptide \[SLc: K2-(SL)3 (RG) (SL)3-K2\] to study neovascularization \[[@bib101]\]. These peptides could form self-assembled thixotropic, injectable and biodegradable hydrogels, which were injected subcutaneously in a rat model to study angiogenesis. In the case of SLanc peptide, increased vascularization was observed within 7 days of injection as compared to SLc peptide. The authors postulated that the vascularization was promoted due to the easy diffusion of VEGF mimetic peptide from the non-fibrous gel made of SLanc peptide by either simple equilibrium or subsequent proteolysis of the MMP-2 cleavage sites of the peptide ([Fig. 2](#fig2){ref-type="fig"} vii). In another study, the same hydrogel was injected in the hind limb ischemia of mouse \[[@bib102]\]. The synthetic peptide-based hydrogel scaffold promoted angiogenesis and recovery of ischemic tissue. Bio-distribution studies indicated that the hydrogel could be injected safely intramuscularly, subcutaneously, or intravenously. Histology of muscle tissue from SLanc-treated mice on day twenty eight demonstrated the formation of mature blood vessels in the injection site and preservation of tissue structure and function \[[@bib102]\].

3. Conclusion {#sec3}
=============

The use of injectable hydrogel provides a promising therapeutic pathway to promote neovascularization in ischemic tissues and organs. Injectable hydrogels provide an extensive network structure from which trapped angiogenic growth factors release in a slow and sustained manner and subsequently results in the formation and maturation of blood vessels. In cell-based therapies, injectable hydrogels provide an ECM like microenvironment to enhance cellular retention, survival, proliferation and neovascularization. The synthesis of suitable injectable hydrogels, with respect to their mechanical stability and biodegradability, can be a challenging task for efficient neovascularization. Natural polymers are biodegradable but they have poor mechanical stability upon injection, while synthetic polymers have tunable mechanical property but their biodegradation rates are generally very low. Recent attempts have focused on the use of composite or hybrid hydrogels made of natural and artificial precursors to address these limitations. The use of synthetic polymer-based micro/nanoparticals is also another promising candidate for neovascularization due to their moderate degradability and mechanical stability. We believe that polymer-based micro/nanoparticals and new biohybrid injectable hydrogels will significantly impact the field of controlled drug delivery and cell therapeutics. Extensive research continues to be needed on the design and development of growth factor mimetic synthetic peptide-based hydrogels. After successful neovascularization in animal models, future work will be needed to demonstrat the efficacy of injectable materials for therapeutic angiogenesis in primates and humans.
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